LANGHORNE - Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA.

Savara's partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP.

Below are summaries of the posters presented: Poster Board 701: 'Healthcare Burden of Pulmonary Alveolar Proteinosis' presented by E. Lee, M.D., Ph.D.; sponsored by Savara Inc.

Presented data from a retrospective cohort analysis using a longitudinal claims database (IPM.ai) comparing the clinical and economic burden of a sample of 2,312 pulmonary alveolar proteinosis (PAP) patients to 9,247 non-PAP matched controls.

Data demonstrated PAP patients experience higher healthcare resource utilization and higher pharmaceutical and non-pharmaceutical costs as evidenced by a 4-fold increase in hospital admissions, 6-fold increase in in-patient visits, and a 4-fold increase in cost of care, as well as higher rates of comorbidities, procedures, and therapy use (all parameters p

(C) 2024 Electronic News Publishing, source ENP Newswire